BiotechTube

Selumetinib + Durvalumab

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma

Conditions

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer, Recurrent Nonsmall Cell Lung Cancer

Trial Timeline

May 1, 2018 → May 1, 2024

NCT ID
NCT03004105

About Selumetinib + Durvalumab

Selumetinib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03004105. Target conditions include Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer, Recurrent Nonsmall Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03004105Phase 2Withdrawn

Competing Products

20 competing products in Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
40
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85